DAIICHI SANKYO TO LEVERAGE RANBAXY'S PRESENCE IN AFRICA FOR MARKETING AND DISTRIBUTION


DAIICHI SANKYO TO LEVERAGE RANBAXY'S PRESENCE IN AFRICA FOR MARKETING AND DISTRIBUTION
Daiichi Sankyo Company Limited ("Daiichi Sankyo") and Ranbaxy Laboratories Limited ("Ranbaxy") announced today that Ranbaxy will launch Olmesartan Medoxomil, an antihypertensive originally discovered by Daiichi Sankyo, in six African countries; Kenya, Mozambique, Nigeria, Tanzania, Uganda, and Zambia. The companies will launch the products under the brand name OlvanceTM, as soon as the necessary measures have been completed in each country.

"I am delighted to announce the introduction of Olvance in Africa through Ranbaxy's network," said Takashi Shoda, President & CEO of Daiichi Sankyo. "This is the first time in Africa that Daiichi Sankyo and Ranbaxy are leveraging mutual synergies generated through the Hybrid Business Model, and we will continue to explore other collaborations with Ranbaxy that will help deliver our innovative products to the patients throughout the globe."

Commenting on the occasion, Mr. Atul Sobti, CEO and Managing Director of Ranbaxy, said, "Ranbaxy has a significant presence in the African continent. We will utilize our strong business network to bring the innovative medicines of Daiichi Sankyo to the African people."

Olmesartan Medoxomil is a member of the Angiotensin receptor blocker (ARB) class of antihypertensive medications that help lower blood pressure by blocking the angiotensin II receptor on the blood vessels and antagonizing the release of hormone which causes salt retention and increased blood volume. Olmesartan Medoxomil is available in more than 50 countries worldwide.

Ranbaxy launched Olmesartan Medoxomil as Olvance® in India in April 2009, followed by the August launch of Ol-VamloTM, a fixed-dose combination of Olmesartan Medoxomil with Amlodipine Besylate.

About Daiichi Sankyo Company, Limited
A global pharma innovator, Daiichi Sankyo Company, Ltd., was established in 2005 through the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research and development are thrombotic disorders, malignant neoplasm, diabetes mellitus, and autoimmune disorders. Equally important to the company are hypertension, hyperlipidemia or atherosclerosis and bacterial infections. For more information, visit www.daiichisankyo.com.

About Ranbaxy Laboratories Limited
Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 48 countries and manufacturing operations in 10 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Daiichi Sankyo is a leading global pharma innovator, headquartered in Tokyo, Japan.
 

 

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.